Abstract:Endoscopy is commonly used for diagnosis and management of patients with inflammatory bowel disease (IBD); however, it is costly, invasive and has known risks of complications. Faecal calprotectin (FC) is a non-invasive biomarker of intestinal inflammation and is highly correlated with endoscopic disease activity. The use of FC testing is not well understood in IBD in a real-world setting. This retrospective cohort study examined the use of FC and subsequent endoscopy for patients who had an FC test vs. those who never had an FC test in Crohn’s disease (CD) and ulcerative colitis (UC) separately. The study, included adult patients (≥18years) with ≥2 diagnosis codes of UC or CD from 2008–2015 in the US Truven Health MarketScan® Commercial Databases. Date of first FC test in the database was defined as index date for FC cohorts; a randomly selected date with an IBD diagnosis claim was defined as index date for non-FC cohorts. Patients were required to have continuous eligibility for ≥6 months before and ≥12 months after index date. Patients in each cohort were propensity score matched (1:1) to have comparable baseline characteristics. Proportions of patients who received endoscopy and average number of subsequent endoscopy procedures performed in CD and UC patients were summarised annually over 3 years post-index date. Trend analyses were conducted to examine whether endoscopy use was different between FC and non-FC cohorts over time. Among 47709 CD patients identified, 981 (2.06%) had FC testing; among 61276 UC patients identified, 522 (0.85%) had FC testing. Of patients who had FC testing, the proportion of subsequent FC testing decreased from year 1 to year 3 post-index date (UC: 22%, 13%, 10%; CD: 17%, 14%, 9%). After matching, FC and non-FC cohorts were comparable in baseline characteristics, including healthcare resource utilisation. Over the 3-year follow-up, trends of endoscopy use differed significantly between FC and non-FC cohorts. FC cohorts’ endoscopy use decreased over the 3-year follow-up (UC: 52%, 32%, 30%; CD: 47%, 29%, 26%), and proportions reduced to less than one-third starting year 2. However, consistently over one-third of patients used endoscopy in non-FC cohorts (UC: 36%, 35%, 38%; CD: 33%, 35%, 33%). Similarly, average numbers of endoscopies per patient decreased in FC cohorts over time (UC: 0.67, 0.40, 0.36; CD: 0.57, 0.36, 0.33) vs. a consistent use in non-FC cohorts (UC: 0.42, 0.46, 0.47; CD: 0.41, 0.46, 0.42). The 3-year trends were significantly different between FC and non-FC cohorts (p < 0.001). Implementation of FC testing has been limited in US clinical practice. Patients with FC testing had reduced endoscopy use over time vs. patients who never received FC testing.

S1302 The When, the Where, and the How: Temporal and Quantitative Trends in Fecal Calprotectin Levels and the Implications for Checkpoint-Inhibitor Colitis

S1271 A Retrospective Study of Treatment Options for Checkpoint-Inhibitor Colitis and Their Impact on Disease Outcomes

S1303 Initial Histologic Presentations of Immune Checkpoint Inhibitor Colitis and Their Differential Disease Outcomes

Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitis

S295 The Impact of Fecal Diversion on Immune Checkpoint Inhibitor Adverse GI Toxicities

S1416 Fecal Calprotectin Completion Patterns in a Mixed Academic-Community Health System

S1161 Gastrointestinal Infection Prior to Immune Checkpoint Inhibition Hinders Treatment Efficacy and Increases the Risk for Checkpoint-Inhibitor Colitis

New strategies in the diagnosis and treatment of immune-checkpoint inhibitor-mediated colitis

Immune Checkpoint Inhibitor-Induced Colitis with Endoscopic Evaluation in Chinese Cancer Patients: a Single-Centre Retrospective Study

The synergy of dual faecal immunochemical and faecal calprotectin testing for accurate assessment of endoscopic and histological activity in inflammatory bowel disease

Cancer Immunotherapy: The Checkpoint between Chronic Colitis and Colorectal Cancer

P641 Faecal calprotectin determines non-response to corticosteroids in patients with immune checkpoint inhibitor colitis

Clinical value of fecal calprotectin

Diagnostic Performance of a Fecal Calprotectin Assay as a Biomarker for Mayo Endoscopic Subscore in Ulcerative Colitis: Result From a Tertiary Referral Center

Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis

Colon Adenoma After Diagnosis of Immune Checkpoint Inhibitor-mediated Colitis

Real-World Use Of Faecal Calprotectin Testing In Patients With Inflammatory Bowel Disease

Novel endoscopic scoring system for immune mediated colitis: A Multicenter Retrospective Study of 674 Patients

Single-cell transcriptomic analyses reveal distinct immune cell contributions to epithelial barrier dysfunction in checkpoint inhibitor colitis

Fecal calprotectin and endoscopic scores: The cornerstones in clinical practice for evaluating mucosal healing in inflammatory bowel disease

Association of Chronic Immune-Mediated Diarrhea and Colitis With Favorable Cancer Response